#15: Life Sciences Investor Road Show - Boston, Pullan Consulting/SJA
Published by
Scott Jordan
on
Life Sciences Investor Road Show Boston, March 5th
Goodwin Procter Conference Center - 2nd Floor 53 State Street Boston, MA 02109
Identifying the Next Breakthrough Life Sciences Investment
Life Sciences investors experienced numerous windfalls in 2011 from successful exits (M&A activity) including Daiichi Sankyo’s acquisition of Plexxikon ($935 million total deal value), and Gilead Sciences’ acquisition of Pharmasset ($11 billion).
Most recently, Avila Therapeutics’ sale to Celgene for $925 million (Phase 1 lymphoma compound) represented a 5x return on aggregate invested capital (upfront) and 15x with downstream earnouts.
Please join us from 5:30-8:30PM on Monday, March 5th, at Goodwin Procter’s offices to hear from 5 promising life sciences companies seeking to be the Next Breakthrough Investment. The event will include a networking reception with cocktails and appetizers. Presenting companies include:
- Myomo, a new generation medical device/robotics company revolutionizing stroke therapy
- Eleison Pharmaceuticals, a specialty pharma company developing therapeutics for rare cancers
- Salarius Pharmaceuticals, an oncology biotechnology company developing novel epigenetic/stem cell therapies
- Bridge to Life, a development-stage biotechnology company seeking to develop organ transplant solutions to assist in high-risk surgical procedures
- Formula Pharmaceuticals, an oncology focused drug development company with a breakthrough immunotherapy for the maintenance of complete remission in AML
We anticipate the audience to include Angel Investors, Venture Capitalists, Private Equity, C-Level Industry Professionals, Family Offices, Physicians, and other Accredited Investors.
S. Jordan Associates (SJA) is a life sciences investment bank located in Chicago specializing in raising private placement capital from institutional and "retail" accredited investors.
For more information regarding SJA, Boston Road Show, and "Crowdfunding," please see our website.